Marcin Frąckiewicz, Author at TechStock²

Oracle’s ‘Truly Awesome’ AI Cloud Quarter Sends Stock Soaring 36%, Making Ellison World’s Richest

Oracle (ORCL) Stock Surges on AI Frenzy – Trillion-Dollar Dreams in Focus

Stock Price & Recent Trading Oracle’s stock price has been volatile but trending up. On Oct. 24, 2025, ORCL traded in the $282.80–$287.19 range and closed at $285.72 (up 2% on the day) economictimes.indiatimes.com. Volume was heavy (~1.95 million shares)

24 October 2025

Apple Stock Hits New Heights: iPhone 17 Supercycle, Analyst Split, and 2025 Outlook Revealed

Apple (AAPL) Stock Rockets to Record High on iPhone 17 Hype — What’s Next?

Near-Term Move: Riding the Rally Apple shares have been volatile but are trading very near record levels. On Oct. 20, investors bid the stock up sharply – by the close it was ~$262 (intraday as high as ~$264) ts2.tech. Since then

24 October 2025

Apple · Investing · iPhone · NASDAQ:AAPL · Stock Market · Technology

NV Energy Stock Holds Steady Amid Nevada Utility Turmoil

Stock Performance & Trading NV Energy’s stock is essentially flat this week, closing at $23.74 per share on Oct. 24, 2025 investing.com investing.com. The share price is right at its recent range (previous close $23.74, open $23.71, day’s high $23.75

24 October 2025

Energy Sector · Market Analysis · Nevada · Stocks · Utilities

Grindr Stock Skyrockets on Buyout Buzz – What Investors Need to Know

Buyout Buzz Sends GRND Soaring Grindr’s stock price skyrocketed after news of a potential insider buyout broke. On Friday, Oct. 24, GRND opened at $14.50 and surged as high as $16.22 intraday, an approximately 25% jump from the prior day’s

24 October 2025

Financial News · Investing · LGBTQ+ Business · Mergers & Acquisitions · NYSE:GRND · Stock Market

Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Stock Performance: Clover Health stock has been exceptionally volatile in mid‑October 2025. On Oct. 21 it jumped ~8.7% intraday to ~$3.20 marketbeat.com (from $2.92 prior close), and on Oct. 24 it spiked another ~18%, trading near $3.79 (from $3.20 close

24 October 2025

Analyst Ratings · Financial Analysis · Investment News · NASDAQ:CLOV · Options Trading · Stock Market

Western Union Stock Edges Up on Q3 Beat – CEO Calls Crypto an “Opportunity”

Investors will be watching WU’s short-term outlook as it delivers Q4 results and commentary. Wolfe notes management’s plan to stabilize its core retail business, re-accelerate digital growth, and diversify into new financial services investing.com. In the near term, stock momentum

24 October 2025

Business News · Cryptocurrency · Earnings · Finance · Stocks

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intraday ts2.tech, an increase of about 92%. This surge coincided with reports that VCN-01 had

24 October 2025

Biotech · Cancer Research · Clinical Trials · Investing · NASDAQ:TOVX · Stock Market

The $350B Shake-Up: How AI Summaries Rewire Publisher Traffic

Alphabet Stock Skyrockets to Record High, Nears $3 Trillion on AI Boom & Earnings Hype

Key Facts – October 24, 2025 Alphabet Rallies to Near Record Highs on AI Momentum Google’s headquarters campus in Mountain View. Alphabet’s stock (GOOG) has been on a tear, reaching all-time highs as investors cheer the company’s AI strides and

24 October 2025

Artificial Intelligence · Earnings Reports · Investment News · NASDAQ:GOOG · Stock Market · Tech Companies

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Key Facts: – Neuphoria (Nasdaq: NEUP) shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial investing.com. The AFFIRM-1 trial missed both primary and secondary endpoints, and the company immediately

24 October 2025

Biotech · Clinical Trials · Investing · Mental Health · NASDAQ:NEUP · Stock Market

Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?

Stock Price & Recent Movement Picard Medical stock has been extremely volatile this month. After its Aug. 29 IPO at $4.00, PMI traded mostly under $10, but shot higher in mid-October. On Oct. 20 the stock closed around $11.60, then

24 October 2025

Company Updates · Financial Analysis · Investment News · Market Trends · NYSE:PMI · Stock Market

General Dynamics Stock Rockets to Record High on Blowout Q3 Results and Defense Windfall

Blowout Q3 Results and Rising Orders General Dynamics (NYSE: GD) stunned investors on Oct. 24, 2025, with a blowout third-quarter report. The defense and aerospace giant said Q3 revenue was $12.91 billion – about 10.6% higher than a year ago –

24 October 2025

Defense Industry · Earnings Reports · Financial Analysis · Investment News · NYSE:GD · Stock Market

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

Recent FDA Approval and Market Reaction NeurAxis’s Oct. 24, 2025 announcement of FDA 510(k) clearance for its PENFS device immediately grabbed market attention. The clearance authorizes use in adults (8 years and up) for functional abdominal pain associated with FD

24 October 2025

Biotechnology · FDA Approvals · Investment News · Medical Devices · NASDAQ:NRXS · Stock Market